KR102546935B1 - A composition for preventing or improving diabetes containing a radish extract as an active ingredient and a method for producing the same - Google Patents

Abstract

The present invention relates to a composition for preventing or ameliorating diabetes, and when it contains fusiformis extract as an active ingredient, there is no concern about side effects even when taken for a long period of time as natural products are used, and alpha-glucosidase inhibitory activity and blood sugar elevation inhibitory activity and fasting blood glucose lowering activity.

Description

Composition for preventing or improving diabetes containing fusiformis extract as an active ingredient and method for preparing the same

The present invention relates to a composition for preventing or improving diabetes comprising fusiformis extract as an active ingredient and a method for preparing the same. More specifically, a composition for preventing or improving diabetes containing fusiformis extract exhibits alpha-glucosidase inhibitory activity and blood glucose elevation inhibitory activity through a composition for preventing or improving diabetes, and by including natural products It relates to a composition for the prevention or improvement of diabetes comprising fusiformis extract having no side effects even after long-term use as an active ingredient and a method for preparing the same.

In Korea, which has achieved rapid economic development over the past 30 years, the incidence of chronic diseases such as diabetes, hypertension, obesity, and hyperlipidemia has increased as living standards have improved and eating habits and lifestyles have become westernized. Public interest is increasing. Among them, diabetes was found to be the 5th leading cause of death in Koreans investigated in 2010, and according to the Korean Diabetes Association in 2012, 1 out of 10 Korean adults are currently diabetic, and 2 out of 10 are in the latent stage of diabetes. It was analyzed that 3 out of 10 adults are exposed to the threat of hyperglycemia. In addition, it is revealed that if the incidence of diabetes is the same as now, the estimated number of diabetes patients in 2050 will increase to 5.91 million, about twice the current level, and the prevention and treatment of diabetes is a matter of great interest in public health.

Diabetes mellitus is a metabolic disorder caused by impaired secretion and lack of action of insulin secreted from pancreatic cells, accompanied by excessive production of glucose, breakdown of body fat and waste of protein, and abnormal secretion of glucagon, resulting in metabolic confusion. [Abrams JJ, Diabetes. 31: 903-910 (1982)]. In the case of diabetes, it shows characteristic symptoms of hyperglycemia due to abnormal physiological metabolic control functions such as carbohydrate, protein, lipid and electrolyte metabolism due to hormonal imbalance including insulin [Gonuth SM, Ann. Inter. Med. 79: 812-822 (1973)], and if these symptoms of hyperglycemia persist, it causes blood circulation disorders, retinal damage, nerve cell damage, kidney function decline and vascular complications [UKPDS Group,. Lancet. 352: 837-853 (1998)].

Diabetes is largely classified into two types, namely type 1 diabetes and type 2 diabetes. Type 1 diabetes is caused by a lack of secretion of insulin, a hormone that regulates glucose in the blood, and mainly affects young people in their 10s to 20s. occurs in Type 2 diabetes usually develops after the age of 40 and accounts for the majority of diabetic patients. As the etiology of type 2 diabetes, both insulin secretion disorders in pancreatic beta cells and insulin action defects in target cells (insulin resistance) are observed. Insulin resistance is a state in which the action of insulin is reduced in peripheral tissues and is the main cause of type 2 diabetes [Kahn SE, Diabetologia. 46: 3-19 (2003)].

The most important goal in diabetes treatment is to control blood sugar levels as close to normal as possible, and treatment methods include drug therapy, diet therapy, and exercise therapy. There are α-glucosidase inhibitors, sulfonylurea preparations, and biguanide preparations as oral hypoglycemic agents currently used in diabetic patients. It shows the therapeutic effect of diabetes by reducing the rise of blood sugar and blood insulin by delaying digestion and absorption of food. α-glucosidase inhibitors have the advantage of stimulating the secretion of glucagon-like-peptide-1 in the small intestine, which promotes insulin secretion and suppresses glucagon secretion, without causing hyperinsulinemia or hypoglycemia. [Mooradian AD, Drugs. 57: 19-29 (1999); Baron AD, Diabetes Research and Clinical Practice. 40: S54-S55 (1998)].

On the other hand, mammalian α-glucosidase (α-glucosidase) is a digestive enzyme present in the mucosal villi of the small intestine, and promotes the hydrolysis of carbohydrates in the form of oligosaccharides and polysaccharides entering the body into monosaccharides, and sugar is absorbed into the body. Let it be. When the action of α-glucosidase increases and the decomposed glucose increases, the blood sugar level rises, resulting in a hyperglycemic state. Accordingly, α-glucosidase inhibitors are effective in delaying the digestion of carbohydrates in the small intestine, attenuating the postprandial increase in blood glucose levels, and delaying insulin secretion due to hyperglycemia. Commercially available α-glucosidase inhibitors include acarbose, miglitol, and voglibose, which are used to treat type 2 diabetes.

However, the α-glucosidase inhibitors described above may exhibit side effects such as abdominal distension, vomiting or diarrhea in some patients when taken for a long time, and thus their use may be limited. [Hanefeld M, Journal of Diabetes and its Complications. 12: 228-237 (1998)].

Accordingly, the inventors of the present invention are concerned with the prevention or prevention of diabetes, which contains, as an active ingredient, a natural extract exhibiting effects of controlling blood sugar and curing and preventing diabetes, without causing side effects caused by conventionally used α-glucosidase inhibitors. It was intended to provide a composition for improvement.

KR 10-1976941 B1 KR 10-0992527 B1

An object of the present invention is to provide a composition for preventing or improving diabetes comprising fusiformis extract as an active ingredient and a method for producing the same, to provide a composition for preventing, improving or treating diabetes, including fusiformis extract.

In addition, an object of the present invention is to prevent, improve, or treat diabetes through the alpha-glucosidase inhibitory activity and blood glucose elevation inhibitory activity of a composition for preventing or improving diabetes comprising fusiformis extract as an active ingredient to provide an effect.

In order to achieve the above object, the composition for preventing or improving diabetes according to an embodiment of the present invention is to include a fusiformis (Hizikia fusiformis) extract as an active ingredient.

The fucoidan extract is fucoidan.

The composition is characterized in that it exhibits an effect of preventing or improving diabetes through α-glucosidase inhibitory activity and blood glucose elevation inhibitory activity.

A pharmaceutical composition for preventing or treating diabetes according to another embodiment of the present invention includes the composition for preventing or improving diabetes as an active ingredient.

A food composition for preventing or improving diabetes according to another embodiment of the present invention includes the composition for preventing or improving diabetes as an active ingredient.

Method for producing a composition for preventing or improving diabetes according to another embodiment of the present invention comprises the steps of: 1) preparing a mixture by mixing fusiformis and an aqueous calcium chloride solution; 2) a heat treatment and stirring step of heat treatment and stirring of the mixture prepared in step 1); 3) a first separation step of centrifuging the mixture stirred in step 2) to separate only the supernatant; 4) filtering the supernatant separated in step 3) under reduced pressure; 5) a first precipitation step of precipitating the supernatant obtained by filtering under reduced pressure in step 4) in an alcohol solution; 6) a second separation step of separating only the supernatant by centrifuging the supernatant after the first precipitation step of step 5); 7) a second precipitation step of precipitating the supernatant separated in step 6) in an alcohol solution; 8) a third separation step of separating only the precipitate excluding the supernatant by centrifuging the supernatant after the second precipitation step of step 7); and 9) extracting fucoidan by drying the precipitate separated through the third separation step of step 8); includes

Hereinafter, the present invention will be described in more detail.

Throughout this specification, when a certain component is said to "include", it means that it may further include other components without excluding other components unless otherwise stated.

As described above, the term "extract" used throughout this specification has a meaning commonly used in the art as a crude extract, but also includes fractions obtained by further fractionating the extract in a broad sense.

That is, the natural extract includes not only those obtained by using an extraction solvent, but also those obtained by additionally applying a purification process thereto. For example, a fraction obtained by passing the extract through an ultrafiltration membrane having a certain molecular weight cut-off value, separation by various chromatography (made for separation according to size, charge, hydrophobicity or affinity), etc. The fraction obtained through the purification method is also included in the natural extract of the present invention.

Throughout the present specification, "diabetes mellitus" refers to a metabolic disease characterized by a high blood glucose concentration, such as an insufficient secretion of insulin or a failure to function normally. The diabetes may be type 1 diabetes or type 2 diabetes.

Throughout the present specification, "prevention" refers to all activities that inhibit or delay the onset of diabetic symptoms by administration of the composition.

Throughout the present specification, "improvement" or "treatment" refers to all activities that improve or beneficially change the symptoms of diabetes by administration of the composition.

A composition for preventing or improving diabetes according to an embodiment of the present invention is to contain a fusiformis (Hizikia fusiformis) extract as an active ingredient.

The diabetes mellitus is a metabolic disease in which the ability of body cells to use glucose normally is impaired, blood sugar levels increase, and as glucose accumulates in the blood, excess sugar is excreted in the urine, and insulin ( It occurs when the absolute amount of insulin is insufficient or when hormones other than insulin are secreted in large amounts and are relatively insufficient.

The diabetes is divided into two types. First, insulin-dependent type 1 diabetes mellitus is caused by a lack of secretion of insulin, a glucose-regulating hormone in the blood. For this reason, it is also called juvenile diabetes. The type 1 diabetes is a kind of autoimmune disease and is caused by the destruction of beta cells in the pancreatic islets of Langerhans that secrete insulin. Accordingly, type 1 diabetes can be treated by increasing the absolute amount of insulin through insulin administration, pancreas transplantation, islet beta cell transplantation, and the like.

Another type of diabetes, type 2 diabetes mellitus, occurs mainly after the age of 40 and accounts for most of the diabetic patients in Korea. Unlike type 1 diabetes, it is called adult type diabetes and develops for complex reasons, but it is caused by complex effects such as beta cell inactivation, insulin resistance, and chronic inflammatory response.

More specifically, the beta cells do not secrete insulin effectively, or insulin resistance occurs in target cells of insulin, such as muscle cells (or muscles), liver, and fat tissue, resulting in hyperglycemia and various symptoms.

The abnormal secretion of insulin is associated with an increase in blood glucose during fasting, and insulin resistance causes persistent hyperglycemia symptoms after eating.

Hyperglycemia caused by an abnormality in blood sugar control can lead to complications such as inflammation of the peripheral nervous system, eye disease, cardiovascular disease, and kidney damage, and in severe cases, lower limb amputation, vision loss, myocardial infarction, and end-stage renal failure.

Accordingly, it is desirable to control blood sugar as close to normal as possible by alleviating the symptoms of hyperglycemia due to insulin resistance, and current treatment methods include drug therapy, diet therapy, and exercise therapy. Among the drug therapy, oral hypoglycemic agents used in diabetic patients include α-glucosidase inhibitors, sulfonylurea preparations, and biguanide preparations, among which alpha-glucosidase Inhibitors delay the digestion and absorption of carbohydrates in the ingested diet to reduce postprandial blood glucose and blood insulin rises, thereby exhibiting a therapeutic effect on diabetes.

Accordingly, in the present invention, by including fusiformis extract as an active ingredient, alpha-glucosidase inhibitory activity can be exhibited, thereby exhibiting blood glucose elevation inhibitory activity.

The fusiforme (Hizikia fusiforme) is a seaweed belonging to the family Mosquito, and is variously called Hijiki, Toshiraegi, Tobbaegi, Tol, and Green algae.

Young fusiformes are fleshy spatula-shaped and have serrated leaves at the edges, but they are deciduous, and adults have many columnar branches. Branches are pointed at both ends or club-shaped, and some have expanded ends to become bubbles. Genital deposits where reproductive cells are made (生殖器托: small 葉枝 differentiated when the genital sheath is formed) are formed in the form of several clubs in the axilla of the branch. The growth zone of fusiformes ranges from flat or gently sloping bedrock facing the outer sea, up to about 60 cm below the average water level as the upper limit. The place where hibiscus breeds well is in the concave place where the waves move up and down quietly. The growth period is about late summer to early autumn, and the germinated fluid is visible in mid-autumn, and grows rapidly in March to April, growing to around 60 cm or more than 1 m in length. It reproduces after April or May, and then enters the declining period. In addition, it is a perennial seaweed that sprouts from the root in the fall and reproduces with it every year.

Hijiki contains a lot of inorganic salts such as calcium, iodine and iron, so it prevents hardening of blood vessels. As one of the foods, it contains fiber, so it is good for constipation, and the mucous substance enhances the digestive movement of the intestines.

The composition for preventing or improving diabetes of the present invention may exhibit an effect of preventing or improving diabetes by including the hijiki extract extracted from the fusiformis as an active ingredient.

The fucoidan extract is fucoidan.

The fucoidan, also called fucoidan, is a sulfated polysaccharide with a sticky viscous structure and is a component contained in brown algae such as seaweed and kelp. has been

Fucoidan helps excretion of cholesterol, lowers blood cholesterol levels, prevents vascular disease, and prevents obesity from leading to adult diseases.

The composition for preventing or improving diabetes of the present invention may exhibit an effect of preventing or improving diabetes by including fucoidan contained in hijiki as an active ingredient.

The composition for preventing or ameliorating diabetes may further include an extract of japonica japonica, an extract of japonica japonica, and an extract of Gasol pine.

The dog barley (Lapsana apogonoides (Maxim.) J.H. Park & K. Bremer) is a biennial plant of the dicotyledonous plant Asteraceae and is also called jangtukgal and barley. Grows near rice fields. It is 4-20 cm high. There are many hairs all over, but they gradually disappear, and the soft stems are united and branched. The leaves attached to the root are united and spread in all directions, and the leaves attached to the stem are alternate, and the leaves are long oval and look like dandelion leaves. 1-3 leaves attached to the stem fall off from each other, and the lower leaves are similar to the leaves attached to the root. The leaf length is 4~10cm, the width is 1~2cm, and it gradually gets smaller as you go upwards. Yellow flowers bloom in March-June. At first, it is a sloppy corymb, but the branches grow and droop downward, and the peduncle is 1.5-5cm. The involucre is conical, the outer piece is short and hairy, and the inner piece is 5 and the edge is membranous. There are 6-9 small flowers and the length of the corolla is 5-6mm. Fruits are achene, 3-4.5mm long, long oval, brown. Distributed in Korea (Jeju, Jeonnam, Jeonbuk), Japan, and central China.

The skeletal flower tree (Weigela hortensis (Sieb. et Zucc.) K. Koch) is a deciduous shrub of the dicotyledonous hare tree honeysuckle, a deciduous broad-leaved shrub with a height of 2 to 3 m, young branches purplish brown, hairy, and the bark is gray and vertical split into Leaves are opposite, elliptical or egg-shaped, 7-10 cm long, 2.5-5 cm wide, pointed at the end, round or wide wedge-shaped at the bottom, with fine sawtooth on the edge, and white soft hairs on the back side, giving it a whitish color. Petiole is 4-8 mm long. The flower blooms in red in June, hangs 2-3 at the end of the leaf part of the small branch, and the bract is lanceolate or linear. The calyx is completely split into 5 pieces, and the lobe is linear lanceolate, 3-7 mm long, and has spread hairs. The corolla gradually widens like a funnel, is 3-3.5 cm long, and the style comes out. Fruits are capsules, columnar, and seeds have wings. This species has dense white soft hairs on the back of the leaves compared to the common flower tree, so it is white and the flowers are red. Used for ornamental purposes.

The gasol pine (Phyllodoce coerulea (L.) Bab.) is an evergreen small shrub of the dicotyledonous plant Rhododendronaceae Azalea and grows at the top of a high mountain. The height is 10-25 cm, the base is lying on the side, and the branches diverge a lot. The leaves are 4-10 mm, densely formed, and the ends are slightly rounded and line-shaped. There is no hair on the surface, there is one groove, white hairs grow in the middle of the back side, and there are fine sawtooth on the edge. It blooms in july-shaped magenta flowers. Flowers are 7-8mm long, 2-6 at the end of branches, and face downward. Small peduncles are 2-2.5cm long, with glandular hairs and fine hairs that secrete liquid. The stamens do not have hairs, and the sepals are line-shaped or lancet-shaped and have glandular hairs of about 4mm in length. The fruit is a capsule with a length of about 4 mm and ripens in September. Distributed in Korea (South Hamgyong Province, North Hamgyong Province), Japan, northeastern China, Siberia, and North America. Those with white flowers are called for. albida.

In the case where the composition for preventing or improving diabetes further comprises a hibiscus extract, an extract of japonica japonica, and an extract of pine pine, in addition to the fusiformis extract, the synergistic effect of the mixed use of the extracts When the fusiformis extract is used alone It can exhibit superior diabetes prevention or amelioration activity compared to In addition, the degree of acceptability that may fall due to the peculiar taste of the fusiformis extract can be improved by further including the above-mentioned blackberry extract, bone disease flower extract, and gasol pine extract.

Preferably, the composition for preventing or improving diabetes mellitus extract may include 40 to 60 parts by weight of a hibiscus extract, 40 to 60 parts by weight of a japonica extract, 40 to 60 parts by weight of a japonica extract, and 40 to 60 parts by weight of a pine pine extract. there is. In the case of the above range, a synergistic effect of critical significance is expressed as a synergistic effect due to the interaction between the extracts, compared to the case of using the fusiformis extract alone. there will be no

[0021] The extracts of the blackberry extract, the extract of the genus japonica, and the extract of the pine cone are extracted using an extraction solvent selected from the group consisting of water, C ₁ to C ₆ lower alcohols, and mixtures thereof.

Specifically, washing the natural product to prepare the natural extract; drying after washing; pulverizing the natural product after drying; leaching the pulverized product using an organic solvent; drying the sample after leaching; leaching with water; And including the step of leaching, it is possible to obtain a natural extract.

The natural extract extracted using the organic solvent may further include a step of fractionating using an organic solvent.

A method for preparing the extract may be a conventional extraction method in the art, such as an ultrasonic extraction method, a leaching method, and a reflux extraction method. Specifically, it may be an extract obtained by extracting a natural product from which foreign substances are removed by washing and drying with water, alcohol having 1 to 6 carbon atoms, or a mixed solvent thereof, and may be an extract obtained by sequentially applying the solvents to a sample.

In the ultrasonic extraction method, the reaction is performed at 30 to 50° C. for 0.5 to 2.5 hours, and water or alcohol having 1 to 6 carbon atoms may be used as the extraction solvent. Specifically, extraction is performed at 40 to 50 ° C. for 1 to 2.5 hours, and water or 70 to 80% of alcohol having 1 to 6 carbon atoms is used as an extraction solvent.

The leaching method is performed at 15 to 30° C. for 24 to 72 hours, and water or alcohol having 1 to 6 carbon atoms is used as an extraction solvent. More specifically, it is performed at 20 to 25 ° C. for 30 to 54 hours, and the extraction solvent is water or 70 to 80% of alcohol having 1 to 6 carbon atoms.

The reflux extraction method is based on 100 mL of water and alcohol having 1 to 6 carbon atoms, 10 to 30 g of pulverized natural product, 1 to 3 hours of reflux time, and 50 to 100% of alcohol having 1 to 6 carbon atoms or water. More specifically, based on 100 mL of alcohol having 1 to 6 carbon atoms or 100 mL of water, 10 to 20 g of pulverized natural product, 1 to 2 hours of reflux, and 70 to 90% of alcohol or water having 1 to 4 carbon atoms .

The extraction solvent may be used in an amount of 2 to 50 times, more specifically, 2 to 20 times, based on the weight of the sample. For extraction, the sample may be left for leaching in the extraction solvent for 1 to 72 hours, more specifically 24 to 48 hours.

After extraction, the extract can be fractionated by sequentially applying a fresh fractionation solvent. The fractionation solvent used in the fractionation is at least one selected from the group consisting of water, hexane, butanol, ethylacetic acid, ethyl acetate, methylene chloride, and mixtures thereof, and is preferably ethyl acetate or methylene chloride.

After obtaining the extract or fraction, a method such as concentration or lyophilization may be additionally used.

The composition is characterized in that it exhibits an effect of preventing or improving diabetes through α-glucosidase inhibitory activity and blood glucose elevation inhibitory activity.

The alpha-glucosidase is located in the inner membrane of small intestinal epithelial cells, acts as a carbohydrate degrading enzyme, and is called disaccharidase or oligosaccharidase.

Carbohydrates, which are consumed a lot in daily life, are foods containing a lot of starch, and in order for the starch to be absorbed into the body, it must be decomposed by enzymes to form glucose. Since the starch is a macromolecule composed of millions of glucose components connected to each other, glucose decomposition of starch must be performed through an enzyme. The enzyme is secreted from the small intestine, and types of enzymes include alpha-glucosidase, alpha-amylase, and the like. Glucose decomposed in the small intestine through the enzyme is absorbed into the blood.

The alpha-glucosidase (α-glucosidase) quickly converts starch into free glucose in the small intestine, and the converted free glucose is quickly absorbed into the blood in the small intestine, so blood sugar rises. By inhibiting the activity of , it is possible to improve diabetes by suppressing postprandial blood sugar rise.

A pharmaceutical composition for preventing or treating diabetes according to another embodiment of the present invention includes the composition for preventing or improving diabetes as an active ingredient.

The pharmaceutical composition may further include one selected from the group consisting of pharmaceutically acceptable carriers, excipients and diluents.

Specifically, the pharmaceutical composition is formulated in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories and sterile injection solutions according to conventional methods, respectively. can

In the present invention, carriers, excipients, and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, and calcium phosphate. , calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.

Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc. These solid preparations contain at least one excipient, for example, starch, calcium carbonate, It is prepared by mixing sucrose or lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, solutions for internal use, emulsions, syrups, etc., and various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included in addition to water and liquid paraffin, which are commonly used simple diluents. there is.

Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried formulations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents. As a base for the suppository, witepsol, macrogol, tween 61, cacao butter, laurin paper, glycerogeratin and the like may be used.

The pharmaceutical composition of the present invention can be administered in a pharmaceutically effective amount, the term "pharmaceutically effective amount" of the present invention is a reasonable benefit / risk ratio applicable to medical treatment or prevention to treat or prevent disease It means a sufficient amount, and the effective dose level is the severity of the disease, the activity of the drug, the patient's age, weight, health, sex, the patient's sensitivity to the drug, the administration time of the composition of the present invention used, the route of administration and the excretion rate Treatment It may be determined according to factors including duration, drugs used in combination or simultaneous use with the composition of the present invention used, and other factors well known in the medical arts. The pharmaceutical composition of the present invention may be administered alone or in combination with known immunotherapeutic agents. It is important to administer the amount that can obtain the maximum effect with the minimum amount without side effects in consideration of all the above factors.

A food composition for preventing or improving diabetes according to another embodiment of the present invention includes the composition for preventing or improving diabetes as an active ingredient.

At this time, the amount of the extract in the food or beverage may be added at about 0.01 to 15% by weight of the total food weight, and the health drink composition may be added at a rate of about 0.01 to 10g based on 100 ml, but is not limited thereto .

When the food composition of the present invention is a beverage composition, there is no particular limitation on other ingredients except for containing the extract as an essential ingredient in the indicated ratio, and it may contain various flavoring agents or natural carbohydrates as additional ingredients like conventional beverages. can Examples of the aforementioned natural carbohydrates include monosaccharides such as glucose, fructose, and the like; disaccharides such as maltose, sucrose and the like; and polysaccharides such as conventional sugars such as dextrins, cyclodextrins, and the like, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those described above, natural flavoring agents (thaumatin, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) may be used, but are not limited thereto. The ratio of the natural carbohydrates may generally range from about 1 to about 20 g per 100 ml of the composition of the present invention, but may not be limited thereto.

In addition to the above, the composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and enhancers (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its Salts, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohol, carbonation agents used in carbonated beverages, and the like may be included, but may not be limited thereto.

In addition, the composition of the present invention may contain natural fruit juice and fruit flesh for producing fruit juice beverages and vegetable beverages, and these components may be used independently or in combination. The ratio of these additives is not critical, but may be selected in the range of about 0.1 to about 20 parts by weight per 100 parts by weight of the composition of the present invention, but is not limited thereto.

A health functional food for preventing or improving diabetes according to another embodiment of the present invention includes the composition for preventing or improving diabetes as an active ingredient.

"Health functional food" as used in the present invention refers to a food manufactured and processed by extracting, concentrating, refining, mixing, etc. specific ingredients contained in food raw materials or using specific ingredients as raw materials for the purpose of supplementing health. It is a food designed and processed to fully exert the bioregulatory functions of food components such as biodefense, regulation of biorhythm, prevention and recovery of disease, etc. related to disease prevention and recovery. It shall be assumed that all things which also have a function are included.

Method for producing a composition for preventing or improving diabetes according to another embodiment of the present invention includes the steps of: 1) preparing a mixture by mixing fusiformis and an aqueous calcium chloride solution; 2) a heat treatment and stirring step of heat treatment and stirring of the mixture prepared in step 1); 3) a first separation step of centrifuging the mixture stirred in step 2) to separate only the supernatant; 4) filtering the supernatant separated in step 3) under reduced pressure; 5) a first precipitation step of precipitating the supernatant obtained by filtering under reduced pressure in step 4) in an alcohol solution; 6) a second separation step of separating only the supernatant by centrifuging the supernatant after the first precipitation step of step 5); 7) a second precipitation step of precipitating the supernatant separated in step 6) in an alcohol solution; 8) a third separation step of separating only the precipitate excluding the supernatant by centrifuging the supernatant after the second precipitation step of step 7); and 9) extracting fucoidan by drying the precipitate separated through the third separation step of step 8); includes

The step of preparing the mixture of step 1) is a step of mixing the washed fusiformis with an aqueous calcium chloride solution, and various polysaccharides such as alginic acid, fucoidan, and laminarin are mixed in the fusiformis, so that only alginic acid is selectively removed. This is to gelate alginic acid by mixing, and then the gelled alginic acid in steps 2) and 3) is removed.

The fusiformis and calcium chloride aqueous solution may be mixed in a weight ratio of 1:20 to 1:40, preferably 1:30, but is not limited thereto. If the weight ratio of fusiformis and calcium chloride aqueous solution is less than 1:20, that is, if the calcium chloride aqueous solution is less than the above weight ratio, the gelation of alginate contained in fusiformis does not proceed completely in step 2), which is a later step, and step 3) It may be difficult to completely remove alginic acid from, and when the weight ratio of fusiformis and calcium chloride aqueous solution exceeds 1:40, that is, when the calcium chloride aqueous solution is included in excess of the above weight ratio, 1:20 to 1:40 There is no significant difference from the amount of alginic acid formed by mixing in weight ratio, and as calcium chloride is wasted, economic feasibility decreases. Therefore, the weight ratio of fusiformis and calcium chloride aqueous solution is preferably 1:20 to 1:40.

In step 2), the mixture prepared in step 1) is heat-treated and stirred, and the mixture may be stirred for 2 to 6 hours, and the heat treatment temperature range may be 70 to 100 ° C. More specifically, it is preferable to stir at a temperature of 80 to 90° C. for 4 hours. If the stirring time is less than 2 hours, the gelation of alginic acid contained in the hijiki is not completely achieved, and if it exceeds 6 hours, the difference in the degree of gelation is insignificant or similar compared to the case of 2 hours to 6 hours. It is preferable to proceed with stirring for a period of time, but is not limited thereto.

Step 3) is a first separation step in which only the supernatant is separated by centrifuging the mixture stirred in step 2), for 10 to 30 minutes. It may be centrifuged, and at this time, the centrifugation speed condition may be 5000 rpm to 8000 rpm. It is preferably 6500 rpm, but is not limited to examples. If the time for stirring at the preferred centrifugation speed is less than 10 minutes, the separation of the precipitate and the supernatant may not be completely achieved, and if it exceeds 30 minutes, fucoidan may be precipitated, so centrifugation for 10 to 30 minutes It is preferable to proceed with the separation, but it is not limited thereto.

Step 4) is a step of filtering the supernatant separated in step 3) under reduced pressure. The filter paper used is not limited, but it is a filter paper used in a rapid filtration experiment. It is a process to remove alginate formed in the form of a gel, and It is preferable to use qualitative filter paper used for filtering the same organic solids, and it is preferable to use NO.4 (Whatman) filter paper. However, it is not limited thereto.

Step 5) is a first precipitation step in which the supernatant, which has undergone the vacuum filtration step of step 4), is precipitated in an alcohol solution, and is a step for precipitating laminarin contained in the supernatant in addition to fucoidan. The precipitation time for precipitating the supernatant after the step of vacuum filtration in the alcohol solution is preferably 2 to 6 hours. If it is less than 2 hours, the precipitation of laminarin is insignificant, and if it exceeds 6 hours, not only laminarin but also fucoidan As sedimentation occurs, the yield of finally extracted fucoidan may be lowered.

Step 6) is a second separation step of centrifuging the supernatant after the first precipitation step of step 5) to separate only the supernatant, and centrifugation may be performed at a speed of 5000 rpm to 8000 rpm for 10 to 30 minutes. As in the first separation step, the centrifugation speed condition is 5000 rpm to 8000 rpm, preferably 6500 rpm, but is not limited to the example, and the time condition for centrifugation is less than 10 minutes or more than 30 minutes. It is preferable to perform centrifugation for 10 to 30 minutes after fucoidan is precipitated.

Step 7) is a second precipitation step in which the supernatant separated in step 6) is precipitated in an alcohol solution, and is preferably performed for 2 to 6 hours, the same as the precipitation time conditions of the first precipitation step. The second precipitation step is a step for precipitating fucoidan in the supernatant. When the precipitation time of the supernatant after the second separation step is less than 2 hours, the precipitation of fucoidan does not proceed completely, and when it exceeds 6 hours, Since there is no significant difference from the amount of fucoidan precipitated at 6 hours, it is preferable to proceed with the second precipitation step for 2 to 6 hours.

Step 8) is a third separation step in which only the precipitate excluding the supernatant is separated by centrifuging the supernatant that has passed through the second precipitation step of step 7), and proceeds to obtain the precipitate of fucoidan in the supernatant that has passed through the second precipitation step. It is a step to In the third separation step, like the first separation step and the second separation step, the centrifugal speed condition may be 5000 rpm to 8000 rpm, preferably 6500 rpm, but is not limited thereto. In addition, the time condition for performing the centrifugation is preferably performed for 10 to 30 minutes, and if the time is less than or exceeds the above time range, the final fucoidan yield may be lowered.

When the precipitate, not the supernatant, is separated from the supernatant in step 6) without proceeding with steps 7) and 8) and then dried, most of the precipitate contains laminarin, so fucoidan included in the finally dried extract. amount is small or absent.

Therefore, it is most preferable to extract fucoidan by removing laminarin and precipitating fucoidan to improve the final yield of fucoidan, including steps 7) and 8).

Step 9) is a step of extracting fucoidan by drying the precipitate separated through the third separation step of step 8), and drying is performed to extract only fucoidan from the precipitate separated through the third separation step. In the step of doing, the drying method may be a hot air drying method or a freeze drying method, and it is preferable to dry by a freeze drying method, but is not limited thereto. In the step of drying and extracting fucoidan, the drying is preferably performed for 12 to 36 hours, more preferably for 24 hours.

The present invention includes fucoidan, an active ingredient extracted from fusiformis prepared through the method for preparing a composition for preventing or improving diabetes, so that the prevention or improvement activity of diabetes can be more excellent.

The present invention can provide a composition for preventing or improving diabetes comprising fusiformis extract as an active ingredient and a method for preparing the same.

In addition, the present invention has an excellent prevention, improvement or treatment effect of diabetes through the alpha-glucosidase inhibitory activity and blood glucose elevation inhibitory activity of the composition for preventing or improving diabetes containing fusiformis extract as an active ingredient can provide

1 is an experimental result of blood glucose concentration according to time after administration of fucoid extract (fucoidan) according to an embodiment of the present invention.
2 is an experimental result of measurement of serum glucose and blood glycosylated hemoglobin concentrations according to administration of fucoid fusiformis extract (fucoidan) according to an embodiment of the present invention.
3 is a flowchart of a method for preparing a composition for preventing or improving diabetes according to an embodiment of the present invention.

Hereinafter, embodiments of the present invention will be described in detail so that those skilled in the art can easily implement the present invention. However, the present invention may be embodied in many different forms and is not limited to the embodiments described herein.

[Preparation Example 1: Preparation of extract]

1. Preparation of hijiki extract (H-fucoidan, HF)

After washing the hijiki, the mixture prepared by mixing the hijiki and calcium chloride aqueous solution at a ratio of 1:30 (S1) was stirred at a temperature of 80 to 90 ° C. for 4 hours (S2), and then using a centrifuge at a speed of 6500 rpm Only the supernatant is separated by centrifugation for 20 minutes (S3). The separated supernatant was filtered (S4) using a NO.4 filter paper, and then the filtered supernatant was added to an alcohol solution diluted to 40% and precipitated for 4 hours (S5), using a centrifuge at 6500 rpm Centrifuged for 20 minutes to separate only the supernatant again (S6). The separated supernatant was precipitated again in an alcohol solution diluted to 70% (S7), and then centrifuged at 6500 rpm for 20 minutes using a centrifuge to separate only the precipitate except for the supernatant (S8), and the separated precipitate was 24 A fusiformis extract (HF1) was prepared by freeze-drying (S9) using a lyophilizer for a period of time.

In order to evaluate the yield of fucoidan according to whether or not the steps S7 and S8 are included, except for steps S7 and S8, after step S5, the precipitate other than the supernatant is separated (S6'), and the separated precipitate is frozen for 24 hours. A fusiformis extract (HF2) was prepared by freeze-drying (S6'') using a dryer.

<Preparation step of fusiformis extract (HF)>

S1: Preparing a mixture by mixing fusiformis and an aqueous solution of calcium chloride

S2: heat treatment and stirring step of heat treatment and stirring the mixture prepared in step S1

S3: A first separation step of centrifuging the mixture stirred in step S2 to separate only the supernatant

S4: filtering the supernatant separated in step S3 under reduced pressure

S5: first precipitation step of precipitating the supernatant, which has undergone the step of filtering under reduced pressure in step S4, in an alcohol solution

S6: A second separation step of separating only the supernatant by centrifuging the supernatant after the first precipitation step of step S5

S7: Second precipitation step of precipitating the supernatant separated in step S6 in an alcohol solution

S8: A third separation step of centrifuging the supernatant that has passed through the second precipitation step of step S7 to separate only the precipitate except for the supernatant

S9: extracting fucoidan by drying the precipitate separated through the third separation step of step S8

S6 ': Sediment separation step of centrifuging the supernatant after the first precipitation step of step S5 to separate only the precipitate

S6'': extracting fucoidan by drying the precipitate separated through the precipitate separation step of step S6' for 12 to 36 hours

[Experimental Example 1: Yield evaluation of fucoidan]

In order to evaluate the yield of fucoidan of HF1 and HF2 prepared with a difference in the preparation step of fucoid fusiformis extract in Preparation Example 1, the yield of fucoidan obtained was calculated according to the formula below, and the results are shown in Table 1 below.

Yield of fucoidan (%) = weight of fucoidan / weight of fucoidan × 100

division HF1 HF2 transference number(%) 5.4 2.2

(unit : %)

Referring to Table 1, it can be confirmed that the yield of fucoidan varies greatly depending on the manufacturing method, which is due to the difference between steps S7 and S8. Steps S7 and S8 precipitate the supernatant separated after steps S5 and S6 once again in an alcohol solution diluted to 70%, and then centrifuge the precipitated supernatant to separate only the precipitate excluding the supernatant, It can be confirmed that the fucoidan contained in the supernatant is precipitated by proceeding with the steps S7 and S8, thereby improving the final production yield of fucoidan.

Accordingly, it can be seen that the extraction yield of fucoidan is further improved when the steps S7 and S8 of the present invention are included.

[Preparation Example 2: Preparation of extract]

1. Manufacture of Blackberry extract

After washing and drying the black barley, it was pulverized to prepare a pulverized product. The pulverized product and ethanol diluted with 30% of the extraction solvent were added at a ratio of 1:10 (w;v), completely immersed, and then extracted three times for 2 hours while refluxing at 80 ° C. The extract was filtered and concentrated to prepare a GE extract.

2. Manufacture of other natural extracts

[0085] The sagebrush extract (KE) and Gasol pine extract (SE) were prepared using the same method as the above extract (GE).

3. Preparation of complex extracts

In order to confirm the synergistic effect by mixing, a composite extract was prepared according to the composition shown in [Table 2] below.

M1 M2 M3 M4 M5 M6 M7 M8 M9 HF1 100 100 100 100 100 100 100 100 100 GE - 50 - - 30 40 50 60 70 KE - - 50 - 30 40 50 60 70 SE - - - 50 30 40 50 60 70

(unit: parts by weight)

[Experimental Example 1: Alpha-glucosidase inhibitory activity]

A solution was prepared by dissolving the extract (H-fucoidan, HF1) prepared in Preparation Example 1 in dimethyl sulfoxide at a concentration of 0.5 mg/mL, and then alpha-glucosidase inhibitory activity was measured by the Watanabe method [Watanabe J, et al. al., Biosci. Biotechnol. Biochem, 61, 177-178 (1997)]. Hijiki extract (H-fucoidan, HF1) was put into an enzyme reaction solution containing yeast alpha-glucosidase to measure the degree of inhibition of alpha-glucosidase.

Yeast alpha-glucosidase used in this experiment was purchased from Sigma (Sigma, Louis, MO, USA), and pyranoside (paranitrophenyl-alpha-D-glucopyranoside) was used as the enzyme substrate, as a positive control. used Acarbose (trade name: Glucovi, Bayer-Korea), which is clinically used as a blood glucose elevation inhibitor. For comparison of the resultant values, the alpha-glucosidase inhibitory activity of acarbose was set as an index of 1 and the resultant values were expressed as a comparison multiple. The index value below shows that the higher the number, the better the alpha-glucosidase inhibitory activity, and the measurement was repeated three times, and the results are shown in Table 3 below.

H-fucoidan acabos Alpha-glucosidase inhibitory activity 9.1 One

(Unit: index)

According to Table 3, when treated with acarbose, the alpha-glucosidase inhibitory activity is index 1, whereas when treated with fucoidan (H-fucoidan, HF1) extracted from hijiki, the index is 9.1, which is superior to alpha-glucosidase extract. It was confirmed that it exhibited sidase inhibitory activity.

[Experimental Example 2: Blood Glucose Elevation Inhibiting Activity]

In order to measure the in vivo hypoglycemic effect of fucoidan (HF1) extracted from hijiki, which showed excellent alpha-glucosidase inhibitory activity in an in vitro experiment, the following experiment was performed.

More specifically, after purchasing 5-week-old male C57BL / 6J (n = 15), they were allowed to freely consume water and chow until their weight was 25 to 30 g, temperature (23 ± 2 ° C), Humidity (55 ± 10%) and light/dark cycle (12 hours) were automatically controlled and bred.

In order to measure the postprandial hypoglycemic effect of fucoidan (H-fucoidan, HF1) extracted from fusiformis of the present invention, mice (25-30 g) were tested by egg mass method for control group (n = 5), barley tree group (n = 5), and acarbose It was divided into groups (n=5). The control group was administered with only maltose (1 g/kg), the fucoidan-administered group was administered with maltose (1 g/kg) and fucoidan (H-fucoidan, HF1) (500 mg/kg) extracted from fusiformis, and the acarbose-administered group was administered with maltose (1 g/kg). 1 g/kg) and acarbose (50 mg/kg) were administered. Serum was collected by blood sampling from the tail vein before administration (0 min) and after administration (30, 60, 90 and 120 minutes). Blood glucose was measured by an enzymatic method using a glucose assay kit (Asan Pharmaceutical). The results are shown in Figure 1 and Table 4 below.

Blood glucose level before administration (mg/dl) Blood glucose concentration after administration (mg/dl) hour 0 minutes 30 minutes 60 minutes 90 minutes 120 minutes control group 0 120 65 48 33 Fucoidan (H-fucoidan) administration group 0 48 41 35 24 acarbose
administration group 0 51 43 39 26

(Unit: mg/dl)

Referring to Table 4, in the case of the control group, the postprandial blood glucose increase was 120 mg/dl at 30 minutes after a meal and 65 mg/dl at 60 minutes after a meal, whereas fucoidan (H-fucoidan, HF1) extracted from fusiformis of the present invention It can be seen that in the case of the fucoidan-administered group, blood glucose levels 30 and 60 minutes after meals were significantly lower than those of the control group.

In addition, it was confirmed that in the case of the acarbose-administered group administered with acarbose, which is a positive control group, the blood glucose level was similar to or higher than that of the fucoidan (H-fucoidan, HF1)-administered group extracted from fusiformis of the present invention.

Therefore, the postprandial blood glucose increase of fucoidan (H-fucoidan, HF1) extracted from fusiformis of the present invention was similar to or better than that of the acarbose-administered group, and it was confirmed that the postprandial blood glucose control effect of the diabetic animal model was excellent.

[Experimental Example 3: fasting blood sugar lowering effect]

5-week-old male C57BL/Ks-db/db mice (an animal model for type 2 diabetes) were divided into 3 groups by egg mass method after a 1-week adaptation period. Dietary composition provided AIN-93G diet to the control group (n = 5), and a diet containing 0.6% of fucoidan (H-fucoidan, HF1) extracted from fucoidan (H-fucoidan, HF1) to the fucoidan-administered group (n = 5), positive control group (n = 5) was given a diet containing acarbose (0.06%) for 7 weeks. Animals fed the diet for 7 weeks were fasted for 12 hours and then sacrificed by cardiac blood sampling. Serum glucose concentration (blood sugar) was measured by an enzymatic method using a glucose assay kit (Asan Pharmaceutical). In addition, the concentration of glycated hemoglobin in blood was measured by chromatography using EasyG OneC (Infovia). All results were expressed as the mean ± standard error, and the significance test between each group was performed using one-way ANOVA, and the Tukey's test was used as a post hoc test (p<0.05). The body weight and food intake of each group are shown in Table 5 below. In addition, the serum glucose and blood glycated hemoglobin concentrations of diabetic rats for each group are shown in Table 6 and FIG. 2 below.

group weight (g) Dietary intake (g/d) control group 40.1 ± 1.1 4.1 ± 0.5 Fucoidan (H-fucoidan) administration group 40.8 ± 1.2 4.2 ± 0.4 Acarbose administration group 41.0 ± 0.9 4.0 ± 0.1

(Unit: g, g/d)

group Serum glucose (mg/dL) Blood glycosylated hemoglobin (%) control group 451.8 ± 15.9 8.1 ± 0.4 Fucoidan (H-fucoidan) administration group 315.6 ± 14.7 6.8 ± 0.2 Acarbose administration group 322.4 ± 16.5 7.1 ± 0.2

(Unit: mg/dL, %)

Referring to Table 5, it was confirmed that there was no significant difference in food intake and body weight between the control group, the fucoidan (H-fucoidan, HF1)-administered group, and the acarbose-administered group.

And, referring to Table 6, as a result of measuring serum glucose and blood glycated hemoglobin concentrations for diabetic rats in each group, the group administered with fucoidan (H-fucoidan, HF1) extracted from fusiformis of the present invention compared to the control group It can be confirmed that the serum glucose and blood glycosylated hemoglobin are lower than those of the case of the case.

In addition, as a result of comparing the fucoidan (H-fucoidan, HF1)-administered group with the acarbose-administered group, compared to the acarbose-administered group, the serum Glucose was found to be as low as about 8 mg/dL, and it was confirmed that blood glycosylated hemoglobin (%) was lower in the fucoidan-administered group even in the case of blood glycosylated hemoglobin.

Therefore, it was confirmed that fasting blood sugar can be effectively reduced in the db/db mouse, an animal model for type 2 diabetes, by the fucoidan (H-fucoidan, HF1) extracted from fusiformis of the present invention. It shows that prevention and treatment of diabetes is possible by fucoidan (H-fucoidan, HF1).

[Experimental Example 4: Preventing or improving diabetes mellitus of complex extracts]

To the fucoidan (H-fucoidan, HF1, M1) extracted from the fusiformes prepared in Preparation Example 1, the extract (GE), the genus japonica extract (KE), and the extract (SE) prepared in Preparation Example 2 were added. In order to confirm the alpha-glucosidase inhibitory activity, postprandial hypoglycemic and fasting hypoglycemic effects by further incorporation, only the sample was changed and the experiment was conducted in the same manner as in Experimental Examples 1 to 3 to obtain composite extracts (M2 to M8) Alpha-glucosidase inhibitory activity, postprandial blood glucose lowering and fasting blood glucose enhancing effects were confirmed.

For relative comparison of the above effects, the acarbose administration group was fixed at index 1 in Comparative Example 1, and fucoidan (H-fucoidan, HF1) extracted from hibiscus tested in Experimental Examples 1 to 3 was set at index 3 as Comparative Example 2. , The relative comparison values are shown in Table 7 below.

Comparative Example 1
(Akabos) Comparative Example 2
(M1,HF1) M2 M3 M4 M5 M6 M7 M8 M9 Alpha-glucosidase inhibitory activity One 3 4 4 5 7 8 9 9 8 Postprandial blood sugar lowering effect One 3 5 4 4 8 8 8 9 8 fasting blood sugar lowering effect One 3 4 5 4 8 8 9 9 8

(Unit: index)

According to Table 7, it was confirmed that the composite extracts M2 to M9 showed better experimental results than Comparative Examples 1 and 2 (H-fucoidan, HF1).

In particular, in the case of M2, M3 and M4, alpha- It can be seen that the glucosidase inhibitory activity, postprandial blood glucose and fasting blood glucose lowering effects were slightly increased.

However, compared to the case of containing the above extracts, respectively, in the case of M6 to M8, which are mixed and included in a more preferable weight part, as the activity is further improved, the fucoidan (H-fucoidan, HF1) extracted from the fusiformis of the present invention It was confirmed that the effect of preventing and improving diabetes was excellent when containing 40 to 60 parts by weight of barley plant extract (GE), 40 to 60 parts by weight of kohlrabi extract (KE), and 40 to 60 parts by weight of Gasol pine extract (SE).

[Preparation Example 3: Sensory test]

Preference was evaluated for the M1 to M9. After preparing the above M1 to M8 to M8 as tea, it was provided to 30 adult men and women in their 20s to 50s, and then evaluated for taste and aroma. The evaluation score was requested to be evaluated on a scale of 1 to 10 for each item, and the evaluation results were converted to an average score, rounded off, and shown in Table 8 below. In addition, the index means that the higher the number, the higher the degree of preference.

M1 M2 M3 M4 M5 M6 M7 M8 M9 taste 2 3 3 2 4 6 7 7 4 incense One 3 2 3 4 5 6 7 5 Overall preference (average) 2 3 3 3 4 6 7 7 5

(Unit: index)

Referring to Table 8, in the case of M1, as it contained only fucoidan, it was confirmed that the preference was lowered due to the unique taste and aroma.

On the other hand, it was confirmed that the acceptability of M2 to M4, each containing the extract (GE), the extract (KE), and the extract (SE), was slightly higher than that of M1.

In addition, it was confirmed that M6 to M8 containing all of the extracts in a preferred weight part among M5 to M9 containing all of the extracts exhibited relatively excellent taste and aroma, confirming that it was possible to provide a composition with high preference.

As a result, in the case of containing only fucoidan (H-fucoidan, HF1) extracted from fusiformis, the problem of preference was lower than the effect of preventing and improving diabetes, but the extract (GE) and the extract ( When prepared as a composite composition containing both KE) and Gasol pine extract (SE), the effect of preventing and improving diabetes is maintained or improved, while the taste and aroma are excellent, confirming that it can be supplied as a food or food composition with higher palatability did

Although the preferred embodiments of the present invention have been described in detail above, the scope of the present invention is not limited thereto, and various modifications and improvements of those skilled in the art using the basic concept of the present invention defined in the following claims are also made according to the present invention. falls within the scope of the rights of

Claims (7)

It contains Hizikia fusiformis extract as an active ingredient,
The fucoid extract is fucoidan,
By further containing natural extracts,
The natural extracts are ginseng extract, bone disease flower extract, and gasol pine extract.
A composition for preventing or improving diabetes. delete According to claim 1,
The composition is characterized in that it exhibits an effect of preventing or improving diabetes through α-glucosidase inhibitory activity and blood glucose elevation inhibitory activity
A composition for preventing or improving diabetes. Comprising the composition according to any one of claims 1 and 3
A pharmaceutical composition for preventing or treating diabetes. Comprising the composition according to any one of claims 1 and 3
A food composition for preventing or improving diabetes. Comprising the composition according to any one of claims 1 and 3
Health functional food for preventing or improving diabetes. 1) preparing a mixture by mixing fusiformis and an aqueous calcium chloride solution;
2) a heat treatment and stirring step of heat treatment and stirring of the mixture prepared in step 1);
3) a first separation step of centrifuging the mixture stirred in step 2) to separate only the supernatant;
4) filtering the supernatant separated in step 3) under reduced pressure;
5) a first precipitation step of precipitating the supernatant obtained by filtering under reduced pressure in step 4) in an alcohol solution;
6) a second separation step of separating only the supernatant by centrifuging the supernatant after the first precipitation step of step 5);
7) a second precipitation step of precipitating the supernatant separated in step 6) in an alcohol solution;
8) a third separation step of separating only the precipitate excluding the supernatant by centrifuging the supernatant after the second precipitation step of step 7); and
9) extracting fucoidan by drying the precipitate separated through the third separation step of step 8); including,
The composition prepared through the above step further includes a natural extract,
The natural extracts are ginseng extract, bone disease flower extract, and gasol pine extract.
A method for preparing a composition for preventing or improving diabetes.

Images